Effect of valpromide on the pharmacokinetics of carbamazepine-10, 11-epoxide. 1988

F Pisani, and A Fazio, and G Oteri, and E Spina, and E Perucca, and L Bertilsson
Neurology Clinic, University of Messina, Italy.

The single oral dose pharmacokinetics of carbamazepine-10, 11-epoxide (CBZ-E) were investigated in six normal volunteers during a control session and during concurrent treatment with valpromide (VPM) (300 mg twice daily for 8 days). VPM caused a prolongation of the CBZ-E half-life from 6.4 +/- 1.4 to 20.5 +/- 6.3 h and decreased CBZ-E clearance from 73.5 +/- 20.0 to 23.5 +/- 4.0 ml h-1 kg-1 (P less than 0.01). These results suggest that the elevation of plasma CBZ-E levels in patients receiving carbamazepine and VPM in combination is due to inhibition of epoxide hydrolase in the liver.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002220 Carbamazepine A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties. Amizepine,Carbamazepine Acetate,Carbamazepine Anhydrous,Carbamazepine Dihydrate,Carbamazepine Hydrochloride,Carbamazepine L-Tartrate (4:1),Carbamazepine Phosphate,Carbamazepine Sulfate (2:1),Carbazepin,Epitol,Finlepsin,Neurotol,Tegretol
D005260 Female Females
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000927 Anticonvulsants Drugs used to prevent SEIZURES or reduce their severity. Anticonvulsant,Anticonvulsant Drug,Anticonvulsive Agent,Anticonvulsive Drug,Antiepileptic,Antiepileptic Agent,Antiepileptic Agents,Antiepileptic Drug,Anticonvulsant Drugs,Anticonvulsive Agents,Anticonvulsive Drugs,Antiepileptic Drugs,Antiepileptics,Agent, Anticonvulsive,Agent, Antiepileptic,Agents, Anticonvulsive,Agents, Antiepileptic,Drug, Anticonvulsant,Drug, Anticonvulsive,Drug, Antiepileptic,Drugs, Anticonvulsant,Drugs, Anticonvulsive,Drugs, Antiepileptic
D014635 Valproic Acid A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS. Dipropyl Acetate,Divalproex,Sodium Valproate,2-Propylpentanoic Acid,Calcium Valproate,Convulsofin,Depakene,Depakine,Depakote,Divalproex Sodium,Ergenyl,Magnesium Valproate,Propylisopropylacetic Acid,Semisodium Valproate,Valproate,Valproate Calcium,Valproate Sodium,Valproic Acid, Sodium Salt (2:1),Vupral,2 Propylpentanoic Acid

Related Publications

F Pisani, and A Fazio, and G Oteri, and E Spina, and E Perucca, and L Bertilsson
June 1981, The Journal of pharmacology and experimental therapeutics,
F Pisani, and A Fazio, and G Oteri, and E Spina, and E Perucca, and L Bertilsson
July 1996, Teratology,
F Pisani, and A Fazio, and G Oteri, and E Spina, and E Perucca, and L Bertilsson
October 1977, British journal of clinical pharmacology,
F Pisani, and A Fazio, and G Oteri, and E Spina, and E Perucca, and L Bertilsson
December 1983, British journal of clinical pharmacology,
F Pisani, and A Fazio, and G Oteri, and E Spina, and E Perucca, and L Bertilsson
December 1996, The Journal of pharmacology and experimental therapeutics,
F Pisani, and A Fazio, and G Oteri, and E Spina, and E Perucca, and L Bertilsson
September 1991, Biochemical pharmacology,
F Pisani, and A Fazio, and G Oteri, and E Spina, and E Perucca, and L Bertilsson
March 2020, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences,
F Pisani, and A Fazio, and G Oteri, and E Spina, and E Perucca, and L Bertilsson
September 1996, Journal of the neurological sciences,
F Pisani, and A Fazio, and G Oteri, and E Spina, and E Perucca, and L Bertilsson
June 1993, The Japanese journal of psychiatry and neurology,
F Pisani, and A Fazio, and G Oteri, and E Spina, and E Perucca, and L Bertilsson
July 1988, The Journal of allergy and clinical immunology,
Copied contents to your clipboard!